Austar Lifesciences Limited Provided Group Earnings Guidance for the six months ending 30 June 2023. For the period, the group recorded a net loss of approximately RMB 22 million for the five months ended 31 May 2023 and is expected to record a loss attributable to the owners of the Company as compared with a profit attributable to the owners of the Company of approximately RMB 45.8 million for the six months ended 30 June 2022.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.98 HKD | +11.36% | +28.95% | -37.18% |
26/03 | Austar Lifesciences Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
22/01 | Austar Lifesciences to Swing to Loss; Shares Drop | MT |
1st Jan change | Capi. | |
---|---|---|
-37.18% | 57.67M | |
-3.54% | 185B | |
-0.58% | 109B | |
-2.74% | 68.54B | |
+4.84% | 51.74B | |
+10.40% | 45.22B | |
+3.23% | 41.74B | |
+2.87% | 26.69B | |
+4.61% | 26.83B | |
+11.47% | 25.63B |
- Stock Market
- Equities
- 6118 Stock
- News Austar Lifesciences Limited
- Austar Lifesciences Limited Provides Group Earnings Guidance for the Six Months Ending 30 June 2023